Medicine and Dentistry
Acute Myeloid Leukemia
14%
Autograft
16%
Autologous Bone Marrow Transplantation
28%
Autologous Hematopoietic Stem Cell Transplantation
20%
Autologous Stem Cell Transplantation
15%
Autotransplantation
20%
B Cell
23%
B-Cell Chronic Lymphocytic Leukemia
11%
B-Cell Lymphoma
11%
Bone Marrow Transplantation
42%
Cancer
15%
Chemotherapy Regimens
10%
CHOP
10%
Clinical Trial
13%
Cyclophosphamide
20%
Diffuse Large B-Cell Lymphoma
45%
Disease
73%
Disease Free Survival
11%
Doxorubicin
14%
Drug Megadose
53%
Event Free Survival
12%
Failure Free Survival
14%
Follicular Lymphoma
21%
Granulocyte Macrophage Colony Stimulating Factor
13%
Hemopoietic Growth Factor
9%
High Dose Chemotherapy
25%
Histiocytic Lymphoma
10%
Hodgkin's Lymphoma
56%
International Prognostic Index
15%
Large-Cell Lymphoma
18%
Lymphoma
18%
Malignant Neoplasm
25%
Mantle Cell Lymphoma
17%
Multivariate Analysis
11%
Neoplasm
29%
Non-Hodgkin Lymphoma
100%
Overall Survival
39%
Patient with Non-Hodgkins Lymphoma
11%
Peripheral Stem Cell Transplantation
11%
Peripheral T-Cell Lymphoma
32%
Positron Emission Tomography
12%
Prednisone
11%
Prognostic Factor
11%
Radiation Therapy
14%
Rituximab
17%
Stem Cell
15%
T Cell
14%
Transplantation
30%
Vincristine
13%
Whole Body Radiation
10%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Leukemia
8%
Acute Myeloid Leukemia
13%
Anthracycline
6%
Chemotherapy
47%
Chemotherapy Regimens
5%
Clinical Feature
5%
Clinical Trial
13%
Cyclophosphamide
18%
Cytarabine
7%
Diffuse Large B Cell Lymphoma
15%
Disease
37%
Disease Free Survival
8%
Doxorubicin
15%
Etoposide
5%
Event Free Survival
8%
Failure Free Survival
8%
Follicular Lymphoma
11%
Granulocyte Colony Stimulating Factor
7%
Granulocyte Macrophage Colony Stimulating Factor
9%
Growth Factor
5%
Hematologic Malignancy
5%
Hemopoietic Growth Factor
8%
High Dose Chemotherapy
25%
Histiocytic Lymphoma
7%
Hodgkin Disease
30%
Large Cell Lymphoma
12%
Leukemia
5%
Lymphoma
13%
Malignant Neoplasm
13%
Mantle Cell Lymphoma
6%
Myelodysplastic Syndrome
6%
Neoplasm
15%
Nonhodgkin Lymphoma
59%
Overall Survival
21%
Peripheral T Cell Lymphoma
9%
Phase I Trials
7%
Prednisone
14%
Procarbazine
5%
Progression Free Survival
6%
Remission
36%
Rituximab
10%
Survival Rate
8%
Vincristine
13%
Keyphrases
Acute Myeloid Leukemia
9%
Aggressive Lymphoma
5%
Allogeneic Bone Marrow Transplantation
26%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
22%
Autologous Blood
5%
Autologous Transplantation
8%
Autotransplant
7%
Bone Marrow
9%
Bone Marrow Transplantation
24%
Chemotherapy
20%
Chemotherapy Regimen
7%
Complete Remission
16%
Confidence Interval
6%
Cyclophosphamide
5%
Diffuse Large B-cell Lymphoma (DLBCL)
27%
Disease-free Survival
7%
Doxorubicin
5%
Event-free Survival
5%
Failure-free Survival
5%
Follicular Lymphoma
12%
Granulocyte Colony-stimulating Factor (G-CSF)
7%
Hematological Malignancies
5%
Hematopoietic Growth Factors
7%
High-dose Chemotherapy
17%
High-dose Therapy
18%
Histiocytic Lymphoma
7%
Hodgkin Disease
25%
Hodgkin Lymphoma
7%
Initial Treatment
6%
International Prognostic Index
6%
Lymphoid Malignancies
5%
Lymphoma
38%
Malignancy
5%
Mantle Cell Lymphoma
8%
Marrow
5%
Marrow Transplantation
8%
Nebraska
9%
Non-Hodgkin Lymphoma
43%
North America
6%
Overall Survival
14%
Peripheral T-cell Lymphoma
15%
Prednisone
8%
Relapsed Lymphoma
6%
Remission
8%
Survival Outcomes
5%
T-cell Lymphoma
6%
Transplantation
12%
Treatment Outcome
5%